The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) seeks to reduce cancer incidence, mortality, and morbidity in its Northern California catchment area, nationally, and globally. The principles of precision cancer medicine and precision population health systematically and intimately link research and clinical service delivery for patient and population benefit. The HDFCCC builds on the richness of the basic biological insights and the extensive and exceptional clinical research and facilities at UCSF, one of the world's leading health research universities. Moreover, its location in the San Francisco Bay Area allows the HDFCCC to take advantage of one of the most culturally diverse populations and highly innovative and intellectually vibrant environments in the world. This is accomplished through the ten Research Programs supported by seven Shared Resources and clinical and administrative infrastructure.
Director's Overview: Project Narrative The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) seeks to reduce cancer incidence, mortality, and morbidity in its Northern California catchment area, nationally, and globally. The principles of precision cancer medicine and precision population health systematically and intimately link research and clinical service delivery for patient and population benefit.
Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131: |
Lam, Christine; Ferguson, Ian D; Mariano, Margarette C et al. (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103:1218-1228 |
Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408 |
Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279 |
Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380 |
Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485 |
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575 |
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3: |
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607 |
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794 |
Showing the most recent 10 out of 192 publications